Kane starts KBI-4258 study for catheter-related bloodstream infections

By Jennifer Chiou

New York, Sept. 7 - Kane Biotech Inc. said it began an efficacy study for KBI-4258, a coating product for reducing infections associated with central venous catheters.

Kane said that KBI-4258 is a combination of its exclusively licensed dispersinB technology and an antimicrobial agent.

The preclinical study is designed using a recognized in vivo model with two key endpoints: a reduction in bacterial colonization on the catheter surface and a reduction in catheter-related infection, as measured by testing for the presence of bacteria at the site surrounding the catheter.

The Winnipeg, Man., biotechnology company is focused on the development of products to prevent and disperse bacterial biofilms.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.